Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis

Read more at globenewswire.com